Q1 2021 Cytokinetics Inc Earnings Call Transcript
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics' First Quarter 2021 Conference Call. At this time, I'd like to inform you that this call is being recorded (Operator Instructions)
I'd now like to turn the call over to Diane Weiser, Cytokinetics' Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Good afternoon, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will kick off the call with an overview of the quarter and recent developments. Then Fady Malik, our EVP of Research and Development, will provide an update on omecamtiv mecarbil, including progress following a recent meeting with FDA and what to expect from upcoming analyses from GALACTIC-HF, the positive Phase III clinical trial of omecamtiv mecarbil as well as recent activities related to METEORIC-HF, the second Phase III clinical trial of omecamtiv mecarbil.
Next, Stuart Kupfer, our SVP and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |